Coherus Oncology

CHRS · NASDAQ

$1.00+$0.0413 (+4.31%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $0.9587

About CHRS

Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. The company is headquartered in Redwood City, California and currently employs 147 full-time employees. The company went IPO on 2014-11-06. LOQTORZI (toripalimab-tpzi) is its immuno-oncology franchise. LOQTORZI is the FDA-approved treatment indicated in combination with chemotherapy for recurrent or metastatic nasopharyngeal carcinoma (NPC) and is also in development for the treatment of additional tumor types. Its CHS-114 pipeline is a highly selective cytolytic CCR8 antibody that specifically binds and preferentially depletes CCR8+ tumor regulatory T cells (Tregs) with no off-target binding. Its Casdozokitug pipeline is a first-in-class, clinical-stage IL-27 antagonist, with demonstrated monotherapy activity in treatment-refractory NSCLC and clear cell renal cell carcinoma (ccRCC) and combination activity in hepatocellular carcinoma (HCC).

Employees: 145
Headquarters: Redwood City, California
Listed: Nov 6, 2014
Sector: Health Care
Industry: Biotechnology
Website: coherus.com

Leadership

Coherus Oncology executives
Name	Title	Since	Age
Dennis Lanfear	—	2010	69
Bryan Mcmichael	—	—	46
Theresa Lavallee	—	—	53
Mats Wahlstrom	—	—	70
Georgia Erbez	—	—	58
Rita Karachun	—	—	61
Lee Newcomer	—	—	73
Charles Newton	—	—	54
Jill O'Donnell-Tormey	—	—	69
Michael Ryan	—	—	70
Ali Satvat	—	—	47
Jami Taylor	—	2025	—

Revenue by product and region

Fiscal year ended Dec 31, 2019: $356.07M total revenue

By product

Net Product Revenue$356.10M100.0%
Net Product Revenue$356.07M100.0%

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Coherus Oncology suppliers and customers
Company	Relationship	Country	Correlation
Avid Bioservices CDMO	Supplier	US	0.82
Innovent Biologics	Supplier and customer	CN	0.66
Model N MODN	Supplier	US	0.65
Pfizer PFE	Supplier and customer	US	-0.24
Shanghai Junshi Biosciences H	Supplier and customer	CN	-0.52
Amgen AMGN	Supplier and customer	US	-0.77
AbbVie ABBV	Supplier and customer	US	-0.80
Baxalta, Inc. BXLT	Supplier and customer	US	—
KBI Biopharma, Inc.	Supplier and customer	US	—
Orox Pharmaceuticals BV	Supplier and customer	NL	—

Similar companies

Companies in the same industry as Coherus Oncology

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.